- Carol Ann
Satler, MD, PhD, FACC, FAHA, FAAP joins the Board of
Directors, adding key clinical experience to guide ongoing
nonclinical development in cardiac and pulmonary diseases -
- Lloyd
Klickstein, MD, PhD joins the Scientific Advisory Board to
provide additional research and translational strategy acumen,
complementing the Company's gene therapy expertise -
- Recent additions highlight Carbon
Bioscience's evolution beyond a novel vector platform company into
pipeline-focused organization with meaningful translational efforts
and line of sight to clinical proof of concept milestones -
WALTHAM,
Mass., May 22, 2024 /PRNewswire/ -- Carbon
Biosciences, a preclinical stage biotechnology company developing
genetic medicines for the treatment of pulmonary and cardiac
diseases, announced the appointment of Carol Ann Satler MD,
PhD, FACC, FAHA, FAAP to the Carbon Biosciences Board of Directors,
and Lloyd Klickstein, MD, PhD to the
Scientific Advisory Board. Dr. Satler joins as Carbon's second
independent Board member. Dr. Klickstein joins Carbon's esteemed
scientific counsel comprised of experts in the field of gene
therapy drug development.
"We are pleased to welcome both Dr. Satler and Dr. Klickstein to
the Carbon Team at this formative time in the company's evolution.
Their respective appointments strengthen our thought leadership and
expertise as we advance our pipeline of cardiac and pulmonary
programs towards the clinic," said Dr. Joel
Schneider, President and Chief Executive Officer of Carbon
Biosciences. "Dr. Satler is a world-class clinician with
demonstrated ability to align ground-breaking science and clinical
strategies to advance blockbuster therapies. Dr. Klickstein is a
renowned translational biology expert with significant leadership
and advisory experience from early research through global Phase 3
development across a range of biopharmaceutical organizations."
"Carbon's proprietary knowledge of novel viral vectorization
shows immense potential to surpass the limitations currently
impeding gene therapy programs," expressed Dr. Satler. "I am eager
to support the team in their ambitious goals." Dr. Satler is a
physician executive with demonstrated success in clinical
development and medical affairs in high growth, innovative
companies. Her work has included strategic clinical development
planning, launching and commercialization of products for chronic
diseases such as idiopathic pulmonary fibrosis and heart failure.
Dr. Satler currently serves as lead medical director for the
clinical development idiopathic pulmonary fibrosis program at
Puretech Health and as an Independent Board Member for ViCardia
Therapeutics. She was previously President, Chief Medical Officer
and Board Member of Respira Therapeutics.
Dr. Satler is a graduate of the MD-PhD program at Case Western Reserve University, Cleveland, Ohio. She trained and practiced in
both pediatric medicine and cardiology at Boston Children's
Hospital and served on the faculty of Harvard
Medical School. She has been elected a Fellow of the
American College of Cardiology, American Heart Association, and
American Academy of Pediatrics.
"Carbon's technology shows exciting potential and I look forward
to helping translate the Company's impressive vectorology efforts
and nonclinical research into successful development programs,"
said Dr. Klickstein upon joining Carbon's Scientific Advisory
Board. Dr. Klickstein is a veteran life sciences leader with nearly
20 years of experience, most recently as founding Chief Executive
Officer and subsequently President & Chief Scientific Officer
at Versanis Bio (Acquired by Eli Lilly and Company in 2023). Dr.
Klickstein previously had served for 13 years as a Head of
Translational Medicine at the Novartis Institutes for Biomedical
Research (NIBR). Prior to Novartis, he directed an NIH-funded basic
science laboratory at the Brigham & Women's Hospital (BWH) in
Boston, MA where he also
maintained an active clinical practice. Dr. Klickstein graduated
with MD and PhD degrees from Harvard
University, completed post-graduate clinical training at
BWH, was Board-certified and re-certified in Internal Medicine and
Rheumatology & Immunology and is a Fellow of the American
College of Rheumatology.
Collectively, Dr. Satler's and Dr. Klickstein's backgrounds
enable them to advise Carbon's translational and early phase
clinical activities. They are well positioned to ensure the
Company's rigorous scientific packages inform efficient clinical
development plans that include a biomarker strategy for early
signal detection. The appointments of Dr. Satler and Dr. Klickstein
serve as further recognition of the potential of Carbon's
technology and the near-term inflections towards which the company
is advancing rapidly.
About Carbon Biosciences:
Carbon Biosciences is a team of passionate drug developers
extending the reach of genetic medicines for the treatment of
devastating diseases. We combine the genetic diversity and potency
of viruses that have evolved over millions of years with the recent
clinical and manufacturing advances in the gene therapy field. Our
proprietary platform, PAVE, has the potential advantages of
exquisite tissue specificity, larger payloads and durable treatment
strategies across multiple modalities. Our goal: realize the power
of natural viral evolution and deliver on the promise of genetic
medicines.
Carbon Biosciences, Inc.
Investor and Media
Contact
Beckett Hart
IR@carbonbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carbon-biosciences-announces-new-appointments-to-board-of-directors-and-scientific-advisory-board-302152125.html
SOURCE Carbon Biosciences